An increasing availability of biosimilars is an important step in the process of delivering optimal care while improving access for patients with cancer. Evolving regulatory mechanisms deal with biosimilars with different approaches within major regulatory agencies. We discuss some of the specific properties of biosimilars that merit attention in terms of optimizing their safety, delivering on appropriate related cost savings, and ensuring that appropriate premiums on innovative research are available to ensure ongoing progress in anticancer therapy.
CITATION STYLE
McKoy, J. M., & Giles, F. J. (2019). Biosimilars: Are they really safe? In Cancer Treatment and Research (Vol. 171, pp. 61–73). Springer International Publishing. https://doi.org/10.1007/978-3-319-43896-2_5
Mendeley helps you to discover research relevant for your work.